Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.

ABSTRACT:

Purpose

Anthracycline-induced congestive heart failure (CHF) is a rare but serious toxicity associated with this commonly employed anticancer therapy. The ability to predict which patients might be at increased risk prior to exposure would be valuable to optimally counsel risk-to-benefit ratio for each patient. Herein, we present a genome-wide approach for biomarker discovery with two validation cohorts to predict CHF from adult patients planning to receive anthracycline.

Experimental design

We performed a genome-wide association study in 3,431 patients from the randomized phase III adjuvant breast cancer trial E5103 to identify single nucleotide polymorphism (SNP) genotypes associated with an increased risk of anthracycline-induced CHF. We further attempted candidate valida

SUBMITTER: Schneider BP 

PROVIDER: S-EPMC5215621 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature